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In gastric cancer, a new epigenetic mechanism of tumour suppres-
sor loss has been suggested where the histone methyltransferase
enhancer of zeste homolog 2 (EZH2) is responsible for loss of
expression of RUNX3. This is consistent with EZH2 upregulation
in multiple cancer types being associated with poor prognosis. We
investigated whether EZH2 influences the expression of RUNX3 in
colorectal cancer (CRC) and whether this is independent of meth-
ylation. We determined protein and messenger RNA (mRNA) levels
of EZH2 and RUNX3 and assessed RUNX3methylation with meth-
ylation-specific polymerase chain reaction using 72 human CRCs
and 8 CRC cell lines. We assessed the effect of efficient RNA
interference-mediated knockdown of EZH2 on RUNX3 levels, cell
viability and H3K27 trimethylation of the RUNX3 promoter using
chromatin immunoprecipitation. Despite higher levels of EZH2 and
lower levels of RUNX3 in CRC specimens in general, no inverse
correlation between EZH2 and RUNX3 in paired samples was
found arguing against a major role for histone methylation in
silencing RUNX3 in CRC. Conversely, downregulation of RUNX3
mRNA in the same tumours was associated with RUNX3 DNA
methylation (P < 0.05). In cell lines, knockdown of EZH2 removed
the repressive chromatin marks from RUNX3 but did not result in
RUNX3 re-expression. However, it prevented the re-silencing of
RUNX3 after the removal of demethylating agents. In conclusion,
DNA methylation is primarily responsible for the transcriptional
silencing of RUNX3 in CRC, but EZH2 and histone methylation
are necessary for its methylation-dependent re-silencing after the
removal of demethylating agents. These results would predict that
inhibitors of EZH2 and histone methylation would enhance the
effects of demethylating agents in cancer therapy.
Introduction
Chromatin changes have long been associated with cancer. The best
characterized alteration is CpG DNA hypermethylation, which often
accumulates in promoter regions of tumour suppressor genes, thereby
contributing to tumour suppressor loss through epigenetic silencing.
In addition to DNA methylation, epigenetic modification states of
histones are also implicated in oncogenesis. Particular global patterns
of acetylation and methylation of histones H3 and H4 are associated
with multiple cancer types. These and other findings promote an
emerging view that epigenetic changes in the cancer cell genome
may contribute just as significantly to disease progression as do
genetic alterations to DNA sequence. However, epigenetic changes
can potentially be reversed with inhibitors that block the relevant
chromatin-modifying enzymes. Thus, it is important to better under-
stand the role of these epigenetic enzymes in cancer cells with an
eventual goal of developing new cancer treatments.
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of
polycomb-repressive complex 2 (PRC2), which is a highly conserved
histone methyltransferase that targets lysine-27 of histone H3. This
methylated H3K27 chromatin mark is commonly associated with
silencing of differentiation genes in organisms ranging from plants
to flies to humans. Studies in human tumours show that EZH2 is
frequently overexpressed in a wide variety of cancerous tissue types,
including prostate and breast and is associated with poor prognosis
(1,2). Functional links between EZH2-mediated histone methylation
and DNA methylation suggest that the two mechanisms may act in
partnership (3) but the mechanistic contributions of EZH2 to cancer
progression have not yet been determined.
The same genes that are silenced by methylation of both alleles in
cancer are marked with H3K27 methylation in normal cells also
suggesting that the two phenomena are linked. However, H3K27
methylation is not sufficient in itself to recruit DNA methyltrans-
ferases in normal cells and other unknown changes occurring during
carcinogenesis must control whether promoter methylation ultimately
occurs (4). Although some authors have shown that DNA methylation
and complete transcriptional silencing of cancer genes persist after
depletion of EZH2 (5), others have found that depletion of EZH2 is
sufficient to lead to the upregulation of gene expression independently
of changes in the promoter methylation status. Fujii et al. demon-
strated an inverse correlation between EZH2 and RUNX3 gene
expression in gastric cancer cell lines and an inverse relationship of
these proteins at the individual cell level in human gastric cancer
specimens in the absence of DNA methylation in the RUNX3 pro-
moter region. RNA interference-mediated knockdown of EZH2 re-
sulted in an increase in expression of the RUNX3 gene and was not
associated with any change in DNA methylation status (6), suggesting
that EZH2 can be primarily responsible for the silencing of tumour
suppressor genes independently of other factors in gastric cancer.
If confirmed, this is highly significant finding.
RUNX3 belongs to the RUNX family of genes, which play impor-
tant roles in mammalian development and neoplasia (7–10). RUNX
proteins form complexes with Smad2 and Smad3 that transmit trans-
forming growth factor b/activin signals (11). RUNX3 gene is local-
ized at the 1p36 locus and has been linked to gastric epithelial
homeostasis and gastric carcinogenesis. The 1p36 region is thought
to harbour one or several tumour suppressor genes since this region
exhibits frequent loss of heterozygosity events in colon, gastric, breast
and ovarian cancers (12), and the introduction of a normal human
1p36 chromosome fragment into colon cancer cells suppresses their
tumourigenicity (13). A considerable proportion of gastric cancers do
not express RUNX3 due to hemizygous deletion and hypermethylation
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of the RUNX3 promoter region (14). The hypermethylation of the
RUNX3 promoter has also been found in 21% of colon cancer speci-
mens and 65% of colon cancer cell lines, suggesting that RUNX3 also
has a tumour suppressive function in colorectal cancers (CRCs) (15).
Moreover, it has been shown that RUNX3 attenuates Wnt signalling,
which is overactivated and plays a major role in CRC, through
interaction with the b-catenin/transcription factor 4 complex and re-
duction of its transactivating potential (16).
In the present study, we aimed to investigate the role of EZH2 and
RUNX3 in sporadic CRCs and CRC cell lines and specifically
whether EZH2-mediated chromatin changes are responsible for
RUNX3 gene silencing and therefore represent a new mechanism of
tumour suppressor loss.
Materials and methods
Cell culture
CACO2, DLD1, SW480, LOVO, SW48, HT29, RKO and HCT116 colon
cancer cell lines were obtained from the American Type Culture Collection
and cultured in Dulbecco’s modified Eagle’s medium (Gibco, Paisley,
Scotland) with 4.5 g/l glucose and L-glutamine, penicillin (50 U/ml), strepto-
mycin (50 lg/ml) and 10% fetal calf serum (Gibco).
Immunoblotting
Cells were scraped into sample buffer (125 mM Tris/HCl, pH 6.8, 4% sodium
dodecyl sulfate, 2% b-mercaptoethanol, 20% glycerol, 1 mg bromophenol
blue). Protein concentration was measured using the RC DC protein assay
kit (Bio-Rad, Hercules, CA). The lysates were sonicated and then heated at
95 for 5 min. Fifty micrograms of protein was loaded onto sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and blotted onto polyvinylidene
difluoride membrane (Millipore, Bedford, MA). The blots were blocked in
block buffer (2% low fat milk powder in Tris-buffered saline with 1% Triton)
and incubated overnight at 4C with primary antibody in Tris-buffered saline
with 1% Triton with 0.2% low fat milk powder. Primary antibodies to EZH2
(mouse monoclonal, 1:1000) were from BD Transduction Laboratories (Breda,
The Netherlands), to active form of RUNX3 (mouse monoclonal R3-5G4,
1:200) were from Abcam (Cambridge, UK) and actin (rabbit polyclonal) were
from Santa Cruz Biotechnology (Santa Cruz, CA). Blots were then incubated
for 1 h at room temperature in 1:2000 horseradish peroxidase-conjugated
corresponding secondary antibody (Dako, Glostrup, Denmark) in block buffer.
Finally, blots were developed using Lumilite Plus (Roche, Woerden, The
Netherlands) and a Lumi-Imager (Bio-Rad).
Selection of patient material
Tissue from 72 CRC cases from the archives of the Pathology Department at
the Academic Medical Centre, Amsterdam, was used for the compilation of the
tissue microarray (TMA). The clinicopathological characteristics of patients
used in the TMAs used in this study have been described previously (17). For
the RNA isolation, frozen tissue from 47 CRC patients from archive of Gas-
troenterology and Hepatology Department of Leiden University Medical Cen-
ter was used. The study was performed according to the instructions and
guidelines of the Academic Medical Center (Amsterdam) and Leiden Univer-
sity Medical Center Medical Ethics Committees.
Construction of the tissue microarray
A Manual Tissue Arrayer MTA-1 (Beecher Instruments, Sun Prairie, WI) was
used for the construction of the TMA. Three cores of tissue from each cancer
specimen were used and for each cancer case one core from the corresponding
normal colon.
Immunohistochemistry
TMA blocks were sectioned (4 lm), deparaffinized, immersed in 0.3% H2O2 in
methanol for 20 min and heat treated at 100C (pH 9) for 10 min. Sections were
blocked with TENG-T [10 mmol/l Tris, 5 mmol/l ethylenediaminetetraacetic
acid, 0.15 mol/l NaCl, 0.25% gelatin, 0.05% (vol/vol) Tween 20, pH 8.0] for
30 min. Slides were incubated with primary antibodies to EZH2 (1:12 000) and
to RUNX3 (1:1000) overnight at 4C in phosphate-buffered saline with 0.1%
Triton and 1% bovine serum albumin. The Powervisionþpoly-HRP detection
system (ImmunoVision Technologies, Daly City, CA) was used to visualize the
antibody-binding sites. Sections were counterstained with haematoxylin. Neg-
ative control sections for all antibodies were processed in an identical manner
after omitting the primary antibody and showed no staining.
TMA analysis
The cellular localization and pattern of immunoreactivity were examined by
two investigators independently in a blinded fashion. Expression was graded
from 0 to 2 for EZH2 (0 5 positive nuclear staining in ,10% of the epithelial
cells, 15 positive nuclear staining in,70% of the epithelial cells, 25 positive
nuclear staining in .70% of the cells), where score 2 was assumed as over-
expression of the EZH2. A dichotomized scale was used to measure the intensity
of the RUNX3 expression. Samples with ,10% positive nuclear or cytoplamic
staining in tumour cells were classified as negative and as positive if .10% of
cells had staining intensity greater than that of negative control slides.
RNA isolation and real-time reverse transcription–polymerase chain reaction
Total RNA was isolated using Trizol (Invitrogen, Breda, The Netherlands)
according to the manufacturer’s instructions. Complementary DNA was syn-
thesized from 1 lg of total RNA using random primers (Promega, Leiden,
The Netherlands) and MMLV-reverse transcriptase (Invitrogen). Polymerase
chain reaction (PCR) for EZH2 and RUNX3 was performed with primers as
in (ref. 6) using iCycler Thermal Cycler and iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression was used to normalize for variance.
Methylation analysis
DNA was extracted using the DNeasy Tissue Kit (Qiagen, Venlo, The
Netherlands). Bisulphite treatment was performed using the EZ DNA
Methylation kit (Zymo Research, Orange, CA) according to the manufacturer’s
instructions. The primer sequences for methylation-specific PCR for RUNX3
were as used in (15) and are depicted in supplementary Figure 1 (available at
Carcinogenesis Online). PCR was performed with 40 cycles of 94C, 67C and
72C of 1 min each, preceded by a 5 min denaturing step at 94C and followed
by a 10 min extension step at 72C. The products were electrophoresed on 5%
agarose gel. Human genomic DNA from peripheral blood lymphocytes was
used as an unmethylated control. Human genomic DNA treated in vitro with
Sss I methyltransferase (New England Biolabs, Beverly, MA) was used as
a positive control for the methylated reaction.
RNA interference
Cells were transfected with either negative control small interfering RNA
(siRNA) or EZH2-targeting siRNA (Ambion, ID 107417; Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands) using DharmaFECT transfection
reagent (Dharmacon, Etten-Leur, The Netherlands) according to the manufac-
turer’s instructions. At various time points after transfection, cells were har-
vested and subjected to real-time reverse transcription–polymerase chain
reaction (RT–PCR) and immunoblotting.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay was performed using Chromatin
Immunoprecipitation Assay Kit, (Upstate, Lake Placid, NY). Five micrograms
of HsK27me3 antibody (Upstate) was used. The two pairs of primers for RUNX3
promoter region were used as in (ref. 6) and are depicted in supplementary
Figure 1 (available at Carcinogenesis Online). Preliminary PCRs were per-
formed to determine the optimal PCR conditions to assure linear amplification
of DNA. PCR products were electrophoresed on a 6% polyacrylamide gel. To
measure the level of HsK27me3 in each immunoprecipitate, the ratios between
the intensity of the PCR product in immunoprecipitated DNA versus input DNA
(total chromatin) amplified by PCR in the linear range were calculated.
Treatment of cells with 5-aza-2#-deoxycytidine (5-aza-dC) and combined
treatment of 5-aza-dC and trichostatin A
Cells were split 24 h before treatment and were then treated with either 5-aza-dC
(5 lM) or 5-aza-dC with trichostatin A (150 nM) for 72 h.
MTT assay
Either 72 or 12 h after transfection of cells with control siRNA or EZH2
siRNA, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution was added (final concentration 0.5 mg/ml, stock solution 5 mg/ml
MTT in phosphate-buffered saline), for 3 h. Cells were lysed in acidified 2-
propanol and absorbance measured at 550–560 nm.
Statistical analysis
Data are shown as mean ± SD if not differently indicated. Statistical analysis
was performed using the Statistical Package of Social Science (SPSS) version
16.0 for Windows. The v2 test and Fisher’s exact test were used as appropriate.
Spearman’s rank correlation coefficient was calculated to analyse the associ-
ation between EZH2 and RUNX3 messenger RNA (mRNA) expression. For
comparison between normally distributed variables of interest, the one-way
analysis of variance was used with Tukey’s multiple comparison test when
appropriate. P, 0.05 was considered statistically significant. Univariate anal-
yses of time to death as a result of cancer were performed using the Kaplan–
Meier method.
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Results
RUNX3 expression is frequently lost and corresponds with
methylation and not EZH2 expression in CRC cell lines
Seven CRC cell lines were investigated for the expression of EZH2
and RUNX3 at protein level by immunoblotting (Figure 1A). EZH2 is
expressed at the protein level in all CRC cell lines tested. RUNX3
protein, however, is expressed only in two cell lines—in microsatellite
unstable (MSI) HCT116 cells known as a cell line with the hyper-
methylator phenotype and in the microsatellite stable (MSS) SW480,
which has no widespread aberrant methylation. This expression pat-
tern concurs exactly with the pattern of methylation of the RUNX3
Fig. 1. Expression of EZH2 and RUNX3 in CRC cell lines and CRC patient specimens. (A) Immunoblots of colon cancer cell lines for EZH2 and RUNX3 with
actin as a loading control. (B) Methylation-specific PCR (MSP) analysis of the CpG island methylation status of the RUNX3 promoter region in CRC cell lines.
PCR products specific for unmethylated (U) and methylated (M) CpG sites were analysed in 2.5% agarose gels. (C) Positive nuclear expression of EZH2 and
RUNX3 in HCT116 and SW480 CRC cell lines by immunofluorescence. (D) Quantitative RT–PCR analysis of EZH2 and RUNX3 expression in CRC cell lines.
(E) Quantitative RT–PCR analysis of EZH2 (linear scale) and RUNX3 expression (log10 scale) in CRC patients. (F) MSP for RUNX3 promoter region MSP
in a subgroup of CRC patients. T1–T5 shows positive methylated and unmethylated signals, whereas T6–T8 shows only an unmethylated band.
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promoter found previously in these cell lines (15). We also repeated
methylation-specific PCR for these seven cell lines and confirmed
these results (Figure 1B). Expression of EZH2 and RUNX3 was also
investigated by immunofluorescence showing positive staining for
both in HCT116 and in SW480 cells (Figure 1C) and positive for
EZH2 and negative for RUNX3 in RKO and DLD1 cells (Figure 3F).
mRNA levels of EZH2 and RUNX3 as judged by real-time RT–
PCR performed in the same cell lines correlate well with the protein
levels (Figure 1D). All cell lines express EZH2 with highest rela-
tive values for LoVo, SW48 and RKO. SW480 and HCT116 exhibit
much higher RUNX3 mRNA level than other cell lines, supporting
the data from western blotting. These results suggest a primary
role for methylation rather than EZH2 in controlling RUNX3
expression.
Downregulation of RUNX3 mRNA in human cancer tissue correlates
significantly with RUNX3 promoter methylation but not with EZH2
overexpression
We next performed quantitative RT–PCR on complementary DNA
from 47 CRCs and corresponding normal tissues. We found that
expression of EZH2 mRNA is significantly increased in tumours
(mean ± SEM 0.00673 ± 0.0003, relative values to GAPDH expres-
sion) compared with normal tissue (mean ± SEM 0.00195 ± 0.0003,
relative values to GAPDH expression) (P , 0.001), whereas RUNX3
mRNA expression was significantly lower in CRCs (mean ± SEM
0.01749 ± 0.003238, relative values to GAPDH expression) compared
with normal specimens (mean ± SEM 0.05301 ± 0.012, relative values
to GAPDH expression) (P , 0.01) (Figure 1E).
When the expression of EZH2 and RUNX3 in cancer specimens
was analysed for the degree of association on a per patient basis, we
did not find a significant correlation (P 5 0.2, Fisher’s exact test),
supplementary Table 1 (available at Carcinogenesis Online). We also
calculated Spearman’s rank correlation coefficient and found no signif-
icant association (r 50.302, P . 0.05, ns), although we see a trend.
We then performed methylation-specific PCR for the RUNX3 pro-
moter region and found a good correlation between CpG island DNA
promoter methylation (27/47 cancers) and downregulated RUNX3
mRNA levels (23/27 cancers) (P, 0.05). Eleven cancers had reduced
RUNX3 mRNA levels without corresponding methylation but
only six of these had upregulation of EZH2. Interestingly, 16 patients
with downregulated RUNX3 expression had both methylation of the
RUNX3 promoter region and upregulation of EZH2 mRNA (Table I,
Figure 1F), suggesting that EZH2 may play a role together with
methylation in the downregulation of RUNX3 expression but is not
absolutely required.
EZH2 protein overexpression does not correlate inversely with
RUNX3 expression
We used a TMA and performed immunohistochemical staining for
EZH2 and RUNX3 on tissue from 72 CRC specimens and correspond-
ing normal tissue. The expression of EZH2 and RUNX3 was further
investigated in normal colon using immunohistochemistry. In normal
tissue, the expression of EZH2 is predominantly localized in the
nuclei of the epithelial cells with a gradient decreasing from crypt
to epithelial surface with low or no expression in the mature colono-
cytes of the surface epithelium (Figure 2A). RUNX3 is expressed in
both epithelial and stromal cells in all corresponding normal tissues.
The cellular staining pattern for RUNX3 in normal tissue is mainly
cytoplasmatic. Weak nuclear positivity in normal epithelial cells con-
trasts with strong nuclear positivity in lymphocytes (which can be used
as an internal positive control) (Figure 2B, supplementary Figure 2 is
available at Carcinogenesis Online).
We found that EZH2 is not expressed in cancers from 9 patients
(12.5%), exhibits positive staining in 9 patients (12.5%) and is over-
expressed in 54 (75%) sporadic CRC specimens (Figure 2C, E and G).
On the contrary, the majority (46 patients, 64%) of cancers show loss
of expression of RUNX3 and only 26 patients (36%) demonstrate
positive RUNX3 staining (Figure 2D, F and G and supplementary
Figure 2 is available at Carcinogenesis Online), showing both cyto-
plasmatic and nuclear staining. We analysed our data in order to look
for associations between EZH2 or RUNX3 expression and several
clinicopathological and biological variables (sex, age, location,
Dukes’ stage and grade of tumours) and no significant associations
were observed (data not shown). Interestingly, we also do not see
differences in expression of EZH2 and RUNX3 between MSS and
MSI tumours, in contrast to a previous study (15). We found that
EZH2 is overexpressed in 45 (75%) versus 9 (70%), positive in 6
(10%) versus 3 (23%) and not expressed in 8 (14%) versus 1 (8%)
of MSS versus MSI tumours (P 5 0.58, ns). RUNX3 staining is
negative in 37 (63%) of MSS versus 9 (69%) of MSI tumours (P 5
0.76, ns), supplementary Table 2 (available at Carcinogenesis On-
line). When we analysed the survival data of patients, we see no
difference in 5 year survival when related to EZH2 or RUNX3 ex-
pression (Figure 3A).
We also analysed whether EZH2 protein overexpression inversely
correlates with RUNX3 expression and in concordance with our find-
ings at mRNA level found no such association (Figure 3B, C, D and E,
supplementary Table 3 is available at Carcinogenesis Online). These
data suggest that EZH2 can only play a role in RUNX3 downregula-
tion in combination with other factors.
Knockdown of EZH2 does not lead to re-expression of RUNX3 in CRC
cell lines
To determine whether EZH2 can independently downregulate
RUNX3 expression, we performed RNA interference-mediated
knockdown of EZH2 in seven CRC cell lines. The immunofluores-
cence analysis in DLD-1 cells showed complete knockdown of EZH2
96 h after transfection with siRNA but no re-expression of RUNX3
(Figure 3F). The level of EZH2 protein expression was undetectable
by western blot in all cell lines, confirming an efficient knockdown
(Figure 4A). Knockdown of EZH2 also resulted in a decrease of
EZH2-specific chromatin repressive marks (HsK27me3) in the
RUNX3 promoter detected by chromatin immunoprecipitation
(Figure 4B) and leads to the re-expression of globin A (supplementary
Figure 3 is available at Carcinogenesis Online), which is known to be
controlled by EZH2-mediated silencing (18). The results of quantita-
tive RT–PCR showed significantly decreased levels of EZH2 mRNA
in all cell lines within 48–96 h after transfection with siRNA
(Figure 4C). No changes in RUNX3 mRNA or protein levels were ob-
served in any of the cell lines, regardless of their baseline expression
of RUNX3 (Figure 4A and C).
In contrast, treatment of DLD1 and LoVo cells with the demethy-
lating agent, 5-aza-2’-deoxycytidine (5-aza-dC) or combined treat-
ment with 5-aza-dC and the histone deacetylase inhibitor
trichostatin A, did lead to a considerable increase in RUNX3 mRNA
level (Figure 4D). These data suggest that EZH2 knockdown is not
sufficient to restore RUNX3 expression in CRC cell lines. To inves-
tigate the possibility that EZH2 knockdown influences the expression
of other unidentified tumour suppressor genes as suggested in prostate
cancer, we assessed the influence of EZH2 knockdown on cell growth
and viability. As seen in Figure 5A, B, C and D, efficient EZH2
knockdown does not affect cell growth or viability as assessed by
the MTT assay.
Table I. Association between RUNX3 methylation and downregulation of
RUNX3 mRNA
EZH2 P
No methylation (%) Methylation (%)
RUNX3 No change
versus N
9 (19.1) 4 (8.5) 0.045
Downregulated
versus N
11 (23.4) 23 (48.9)
Note. N, normal colon tissue.
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Knockdown of EZH2 prevents the re-silencing of RUNX3 after the
removal of demethylating agents
Contrary to findings in gastric cancer, our results provide no evidence
for an independent role for EZH2 in RUNX3 silencing in CRC, but
nevertheless, a considerable proportion of patients with RUNX3
downregulation show both EZH2 overexpression and methylation of
the RUNX3 promoter suggesting that the two processes may still be
linked. It has been shown that genes that are silenced in cancer are
often the same genes marked by EZH2 in normal cells, an observation
suggesting that EZH2 acts mainly upstream of methylation or in its
initiation. We hypothesized that EZH2 might be responsible for the
phenomenon of re-methylation and re-silencing of tumour suppressors
seen when demethylating agents are removed. To test this, we treated
DLD1 cells with 5-aza-dC and trichostatin A for 72 h resulting in re-
expression of RUNX3. In these same cells, we then knocked down
EZH2 and determined RUNX3 expression 72 h later. We found that
EZH2 knockdown prevented the re-silencing of RUNX3 (Figure 5E).
This suggests that even though EZH2 does not play an independent
role in silencing of tumour suppressors in CRC, it is required for the
phenomenon of re-methylation and re-silencing of tumour suppressor
genes after the removal of demethylating agents.
Discussion
EZH2 is the catalytic subunit of the PRC2, which is involved in gene
silencing and histone H3 lysine 27 methylation. In embryonic stem
cells, PRC2 controls the expression of a special set of developmental
genes that must be repressed to maintain pluripotency and that are
poised for activation during embryonic stem cell differentiation.
RUNX3 belongs to this subset of genes (19). EZH2 and DNA meth-
yltransferases co-immunoprecipate in vivo and EZH2 directly con-
trols methylation in a small subgroup of genes in CRC cells (3).
Genes that undergo silencing by de novo methylation in cancer are
the same subset of genes that are marked with the repressive chroma-
tin mark HsK27me3 in normal colonic cells. However, how or if one
leads to the other is unclear as HsK27me3 in normal cells does not
lead to recruitment of DNA methyltransferases and methylation (4). It
is probably that additional changes arising during the process of
carcinogenesis such as those found in leukaemia (20) are required.
In addition, genes, where methylation occurs in only one allele in
combination with mutation or deletion of the other, show no
HsK27me3 in normal cells suggesting that although HsK27me3 tar-
gets a subset of genes for methylation in cancer, methylation can also
be driven by clonal natural selection in genes without pre-existent
HsK27me3.
In a recent publication, it has been shown that the putative tumour
suppressor RUNX3, which is known to be hypermethylated in its
promoter region in 20% of CRCs, is a target for repression by
EZH2, and its expression is inversely correlated with EZH2 expres-
sion in gastric cancer cell lines and gastric cancer specimens. More-
over, the expression of RUNX3 was restored by EZH2 knockdown
while no changes in DNA methylation status of the RUNX3 promoter
were observed, suggesting a crucial role for EZH2 in maintaining
RUNX3 gene silencing independently of promoter methylation and
Fig. 2. Expression of EZH2 and RUNX3 in normal human colon and in CRC specimens using immunohistochemistry. (A) Expression pattern of EZH2 in normal
human colon. (B) Expression pattern of RUNX3 in normal human colon. (C) Positive nuclear EZH2 staining in CRC. (D) Positive RUNX3 expression in CRC.
(E) Overexpression of EZH2 in cancer tissue. (F) Negative expression of RUNX3 in cancer tissue. (G) EZH2 shows negative staining in 9 (12.5%), positive
staining in 9 (12.5%) and is overexpressed in 54 (75%) of CRC patients. RUNX3 is not expressed in 46 (64%) and exhibits positive nuclear or cytoplasmatic
staining in 23 (36%) of CRC patients.
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suggesting a novel mechanism of tumour suppressor inactivation (6).
Other studies confirm that disruption of the PRC2 is sufficient to lead
to the re-expression of a subset of genes in cancer (21).
In this study, we used seven CRC cell lines, extracted RNA from 47
human CRC patient specimens and used a TMA including 72 cancers
to investigate the relationship between EZH2 and RUNX3 expression
in CRC and compare expression with corresponding normal colon
tissue. Here, we show that EZH2 is overexpressed in the majority
of CRCs and significantly upregulated at mRNA level in CRCs com-
pared with corresponding normal tissue. This is in agreement with
a study published while this work was in progress (22). However, in
this study, overexpression of EZH2 was associated with poor patient
survival in a subgroup of Dukes B cancers. In contrast, in 72 CRC
specimens unselected for stage, we do not see a significant difference
in survival associated with EZH2 overexpression. This would be sup-
ported by our findings of unaltered cell growth and viability on EZH2
knockdown. The relatively low number of cases as well as better than
average 5 year survival of the patients in our population (80%) limits
the statistical power of our survival data. However, we do see a signif-
icant association with loss of SMAD4 in the same tumours (R.J.Jacobs,
L.L.Kodach, J.C.H.Hardwick, unpublished results). In contrast to a pre-
vious study, we see no association between EZH2 and RUNX3 expres-
sion and MSI status. Although this could also be attributed to our small
sample size, we have shown a highly significant association between
BMPR2 expression and MSI in the same tumours (17).
Although overall EZH2 mRNA is upregulated in CRC versus cor-
responding normal tissue, RUNX3 expression is reduced, raising the
possibility of a causative relationship. However, we do not find
Fig. 3. Co-localized expression patterns of EZH2 and RUNX3 in CRC specimens. (A) Kaplan–Meier survival analysis of CRC patients according to the
expression of EZH2 and RUNX3. No significant association was found. (B) Overexpression of EZH2 coincides with (C) negative expression of RUNX3.
(D) Overexpression of EZH2 co-localizes with (E) strong nuclear positivity of RUNX3. (F) Immunofluorescence images of CRC cells stained with EZH2 and
RUNX antibodies. Nuclei were stained with 4#,6-diamidino-2-phenylindole. RKO and DLD1 cells show negative expression of RUNX3. The RUNX3 expression
does not change after efficient EZH2 knockdown in DLD1 cells.
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a significant inverse correlation between expression of EZH2 and
RUNX3 on an individual specimen basis, but we do find a significant
association between RUNX3 downregulation and RUNX3 methyla-
tion militating against a primary role for EZH2 in RUNX3 silencing.
Our results are supported by data of Subramaniam et al. (23) showing
that inactivation of RUNX3 was significantly associated with RUNX3
promoter methylation in majority of the colorectal polyps (75%,
P 5 0.022). In the remaining few cases of RUNX3 downregulation
without promoter, hypermethylation was associated with mislocali-
zation of the inactive protein. Interestingly, in our study, 16 of the
27 patients with downregulated RUNX3 expression have both meth-
ylation of the RUNX3 promoter region and upregulation of EZH2
mRNA, which might suggest interplay between EZH2 and methyla-
tion in downregulation of RUNX3 expression.
Similarly, at protein level, we do not see a significant correlation
between EZH2 and RUNX3 expression on an individual patient basis.
In our TMA, EZH2 overexpression is frequently (46%) associated
with loss of RUNX3 staining, but almost as frequently overexpression
of EZH2 coincides with positive RUNX3 expression (30%), suggest-
ing that EZH2 overexpression does not necessarily cause RUNX3
gene silencing and implying that other mechanisms are involved.
Interestingly, we see almost no nuclear staining for RUNX3 in normal
tissue, whereas in some cancer specimens, we notice very strong
nuclear positivity. For a transcription factor, where activity should
correspond with nuclear localization, and a putative tumour suppres-
sor, these results are the opposite of what would be expected. On the
other hand, previously published work has shown strong nuclear
positivity in normal tissue using an antibody they generated them-
selves directed against amino acids 191–300 of RUNX3 (23). This
could be explained by the use of different antibodies, although
we have used a commercially available antibody directed against
the same epitope. Results similar to ours have been obtained in
Fig. 4. EZH2 knockdown is not sufficient to restore RUNX3 expression in CRC cell lines. (A) Immunoblots of colon cancer cell lines for EZH2 and RUNX3 with
actin as a loading control. For every cell line, the first lane is loaded with negative control siRNA-transfected cell lysate and the second lane with EZH2 siRNA-
transfected cell lysate. Despite undetectable levels of EZH2 protein after siRNA-mediated knockdown, RUNX3 protein levels remain unchanged. (B) Chromatin
immunoprecipitation analysis of the RUNX3 promoter in DLD1 cells treated with control or EZH2 siRNA. Two different pairs of primers for RUNX3 promoter
region were used (chromatin immunoprecipitations 1 and 2). Levels of tri-methylated histone 3 K27 are reduced by siRNA-mediated knockdown of EZH2.
(C) Left panel. Quantification of the efficiency of the siRNA-mediated knockdown of EZH2 on mRNA levels. The EZH2 mRNA expression in negative control
siRNA-transfected cells is set at 100%. (C) Right panel. Quantitative RT–PCR shows no differences in RUNX3 mRNA expression after EZH2 knockdown.
(D) Quantitative RT–PCR analysis of RUNX3 mRNA levels in cells treated with 5-aza-2’-deoxycytidine (5-aza-dC) and combined treatment of 5-aza-dC with
trichostatin A (TSA) shows a considerable increase in RUNX3 mRNA level.
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early-onset gastric carcinomas, where RUNX3 protein expression
was not detected in normal tissue, but nuclear RUNX3 staining was
observed in some tumour cells (24). Although others have reported
an association between poorer survival and loss of nuclear RUNX3
expression, this was only true for a small subgroup (9%) where
RUNX3 expression is retained but restricted to the cytoplasm.
This sort of change is probably to be due to mutations in RUNX3
rather than transcriptional silencing due to methylation. No sur-
vival difference was seen between cancers with and without general
cellular RUNX3 expression, a distinction that correlates well with
methylation (25).
In contrast to gastric cancer (6), we do not see re-expression of the
RUNX3 gene after knockdown of EZH2 in a panel of CRC cell lines,
whereas we can restore RUNX3 expression using demethylating
agents. Our data are more consistent with other reports, which show
that EZH2 knockdown causes loss of HsK27me3 at the MLH1 pro-
moter but not gene re-expression or DNA methylation changes (5).
Our data suggest that depletion of EZH2 is insufficient to result in
RUNX3 re-expression in the face of the extensive promoter hyper-
methylation of the RUNX3 promoter found in CRC cell lines and that
CpG island methylation is the principal factor involved in maintaining
the epigenetic silencing of genes in cancer cells.
Although knockdown of EZH2 does not lead to the re-expression of
densely methylated and silenced genes such as RUNX3, we hypothe-
sized that it may nevertheless play a role in marking chromatin for re-
methylation. This is a clinically relevant issue as it is known that
Fig. 5. (A, B, C and D) Efficient EZH2 knockdown does not affect cell growth or viability as assessed by the MTT assay in different CRC cell lines. (E) DLD1
cells were demethylated by treatment with 5-aza-dC and trichostatin A (TSA) for 3 days (72 h) leading to re-expression of RUNX3 mRNA. The same cells were
subsequently transfected either with control siRNA or with EZH2 siRNA and the level of RUNX3 expression was evaluated 72 h after transfection (6 days after the
beginning of the experiment). Knockdown of EZH2 significantly inhibits the re-silencing of RUNX3 after the removal of demethylating agents.
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re-silencing of tumour suppressor genes occurs after the removal of
demethylating agents (26) such as those now in various stages of
clinical testing (27). This is thought to be a major obstacle in success-
ful chemotherapy using these agents. We investigated this by first
demethylating cells and then knocking down EZH2 while removing
the demethylating agents. We show that knocking down EZH2 inter-
feres with the re-silencing of RUNX3 after the removal of demethy-
lating agents, in line with reports suggesting that EZH2 is important in
the regulation of the de novo DNA methylation process.
In conclusion, we find no evidence from expression patterns in
patient material for a role for EZH2 in primarily controlling RUNX3
expression or influencing prognosis. EZH2 knockdown is not suffi-
cient to restore RUNX3 expression, suggesting that even if EZH2 is
a regulator of DNA methylation and gene silencing in cancer, it plays
a limited role after the establishment of dense promoter methylation.
However, EZH2 is involved in promoter re-methylation and the re-
silencing of RUNX3 after the removal of demethylating agents. Strat-
egies aimed at inhibition of EZH2 may have additive effects when
combined with demethylating agents.
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